证券代码：430300 证券简称：辰光医疗 公告编号：2025-077 上海辰光医疗科技股份有限公司 投资者关系管理制度 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 审议及表决情况 上海辰光医疗科技股份有限公司于 2025 年 7 月 8 日召开第五届董事会第 十九次会议，审议通过了《关于制定及修订公司部分内部管理制度的议案》之 子议案 2.22：关于修订《投资者关系管理制度》的议案；议案表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案无需提交股东会审议。 二、 制度的主要内容，分章节列示： 上海辰光医疗科技股份有限公司 投资者关系管理制度 第一章 总则 公司投资者关系管理工作应当严格遵守有关法律法规和北京证券交易所 业务规则的要求，不得在投资者关系活动中以任何方式发布或者泄露未公开重 大信息。公司在投资者关系活动中泄露未公开重大信息的，应当立即通过规定 信息披露平台发布公告，并采取其他必要措施。 第三条 投资者关系管理的目的是： （一）促进公司与投资者之间的良性关系，增进投资者对 ...

二、 制度的主要内容，分章节列示： 上海辰光医疗科技股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、 审议及表决情况 证券代码：430300 证券简称：辰光医疗 公告编号：2025-063 上海辰光医疗科技股份有限公司于 2025 年 7 月 8 日召开第五届董事会第 十九次会议，审议通过了《关于制定及修订公司部分内部管理制度的议案》之 子议案 2.08：关于修订《董事会提名委员会工作细则》的议案；议案表决结果： 同意 9 票，反对 0 票，弃权 0 票。 上海辰光医疗科技股份有限公司 董事会提名委员会工作细则 本议案无需提交股东会审议。 董事会提名委员会工作细则 第一章 总 则 第一条 为规范上海辰光医疗科技股份有限公司董事、高级管理人员的产 生，优化董事会组成，完善公司治理结构，根据《中华人民共和国公司法》、 选择标准和程序进行选择并提出建议，对董事会负责。 第二章 人员组成 第三条 提名委员会成员由三名董事组成，独立董事应当过半数并担任召 集人。 《上市公司独立董事管理办法》（以 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-088 上海辰光医疗科技股份有限公司 证券事务代表任命公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、证券事务代表任命的基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2025 年 7 月 8 日召开第五 届董事会第十九次会议，审议通过了《关于聘任公司证券事务代表的议案》。 聘任陆圣禹先生为公司证券事务代表，任职期限至第五届董事会任期届满之日止， 自 2025 年 7 月 8 日起生效。该人员持有公司股份 0 股，占公司股本的 0%，不是失信联 合惩戒对象。 （上述人员简历详见附件） 二、合规性说明及影响 文件。 上海辰光医疗科技股份有限公司 董事会 陆圣禹先生具备履行职责所必须的专业知识、工作经验及相关素质，能够胜任相关 岗位职责的要求，其任职资格符合《中华人民共和国公司法》、《北京证券交易所股票上 市规则》等相关法律法规的规定。 （二）人员变动对公司的影响 本次聘任证券事务代表对公司生产、经营无重大影响。 三、备查 ...

关于聘任公司内部审计负责人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 为进一步完善上海辰光医疗科技股份有限公司(以下简称"公司")治理结 构，根据《北京证券交易所股票上市规则》、《上海辰光医疗科技股份有限公司章 程》及《上海辰光医疗科技股份有限公司内部审计制度》等相关规定，公司于 2025 年 7 月 8 日召开第五届董事会第十九次会议，审议通过了《关于聘任公司 内部审计负责人的议案》，同意聘任罗妮女士为公司内部审计负责人，任职期限 自公司董事会审议通过之日起至第五届董事会任期届满之日止。 证券代码：430300 证券简称：辰光医疗 公告编号：2025-089 上海辰光医疗科技股份有限公司 截至目前，罗妮女士未直接持有公司股份，与公司董事、监事、高级管理人 员及持有公司 5%以上股份的股东、实际控制人之间不存在关联关系，未受过中 国证监会、证券交易所及其他有关部门处罚和惩戒，不存在因涉嫌犯罪被司法机 关立案侦查或涉嫌违法违规被中国证券监督管理委员会立案稽查的情形，亦不属 于失信被执行人，其任 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2025-055 上海辰光医疗科技股份有限公司 关于取消监事会并修订《公司章程》的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、取消监事会并修订《公司章程》的原因及依据 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司章程指 引》 等规定，由董事会审计委员会行使监事会的相关职权，公司拟取消监事会， 同时废止《监事会议事规则》。 二、修订内容 | 务承担责任。 | | | --- | --- | | 第九条 本公司章程自生效之日 | 第十一条 本公司章程自生效之日 | | 起，即成为规范公司的组织与行为、公 | 起，即成为规范公司的组织与行为、公 | | 司与股东、股东与股东之间权利义务关 | 司与股东、股东与股东之间权利义务关 | | 系的，具有法律约束力的文件，对公司、 | 系的具有法律约束力的文件，对公司、 | | 股东、董事、监事、高级管理人员具有 | 股东、董事、高级管理人员具有法律约 | | 法律约束力的文件。依 ...

Summary of Key Points from Conference Call Records Industry or Company Involved - **AI Glasses**: Multiple significant products are set to be released, including those from Meta and Xiaomi [2][15] - **Liquid Cooling**: National standards for liquid cooling are about to be published, indicating growth in this sector [3] - **Superconductors**: Shanghai Superconductor's IPO application has been accepted, aiming to raise 1.2 billion yuan for high-temperature superconducting materials [4][17] - **POE Particles**: Domestic production of POE particles is being initiated to replace imports [5][16] - **High-end PCB**: Companies like Zhongjing Electronics and Yihua New Materials are involved in high-end PCB production for various applications [6][10] - **Air Conditioning Components**: Shunwei Co. is a leading supplier of air conditioning fan blades, indirectly supplying Xiaomi [7][16] - **Laser Defense Systems**: New developments in lightweight laser defense systems are being tested [12][17] Core Points and Arguments - **AI Glasses Market**: - Meta plans to release new AI glasses with expected sales of 4-5 million units in 2025 [15] - Xiaomi's AI glasses are in small-scale production with projected sales of 300,000-500,000 units [15] - Companies like Biyi Co. and Lianchuang Optoelectronics are heavily involved in AR/VR technologies [15] - **Liquid Cooling Industry**: - The market for liquid cooling servers in China is projected to reach $16.2 billion by 2029, with a CAGR of 46.8% from 2024 to 2029 [3] - Current penetration in data centers is below 10%, indicating significant growth potential [3] - **Superconductors**: - Shanghai Superconductor holds over 80% market share in domestic high-temperature superconducting materials [17] - The company reported a revenue increase of 189% year-on-year, reaching 240 million yuan in 2024 [17] - **POE Particles**: - The domestic market for POE is expected to reach 50-60 billion yuan in 2025, with significant import substitution potential [16] - The company anticipates net profits of 0.5 billion yuan in 2025, increasing to 5.2 billion yuan by 2027 [16] - **High-end PCB**: - Companies are focusing on high-end applications in AI, VR, and gaming, with significant demand for flexible circuit boards [16] - The domestic high-end PCB market is experiencing rapid growth due to increased demand from tech companies [16] - **Air Conditioning Components**: - Shunwei Co. has a global market share of over 35% in plastic air conditioning fan blades [7] - The company is also involved in the low-altitude economy through partnerships in agricultural drone technology [16] Other Important but Possibly Overlooked Content - **Market Dynamics**: The AI glasses market is highly competitive, with major players like Meta and Xiaomi launching new products [15] - **Regulatory Environment**: The upcoming national standards for liquid cooling may streamline the industry and enhance growth prospects [3] - **Investment Opportunities**: Companies involved in superconductors and liquid cooling are positioned for significant growth due to technological advancements and market demand [4][3] - **Financial Performance**: Many companies are reporting substantial year-on-year growth, indicating a robust recovery and expansion in their respective sectors [17][16] This summary encapsulates the critical insights from the conference call records, highlighting the evolving landscape of various industries and the companies poised to benefit from these trends.

Company Overview - Chuangguang Medical's closing price on June 9 was 20.84 yuan, an increase of 4.67%, with a latest price-to-book ratio of 8.15 and a total market capitalization of 1.789 billion yuan [1] - The company specializes in the research, production, and sales of medical imaging superconducting MRI equipment and core hardware, as well as special magnets for scientific research [1] - Major products include nuclear magnetic resonance systems, superconducting magnets, RF detectors, gradient coils, RF amplifiers, and gradient amplifiers [1] - The company is recognized as a high-tech enterprise focusing on independent research and development, having received several accolades including "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" [1] Patent and Intellectual Property - As of December 31, 2024, the company holds a total of 91 valid patents, including 21 invention patents, 60 utility model patents, and 8 design patents [1] - The company has also obtained 5 software copyrights and has 30 domestic patent applications and 6 PCT patent applications under review [1] Financial Performance - For the first quarter of 2025, the company reported revenue of 25.0744 million yuan, representing a year-on-year increase of 20.21% [1] - The net profit for the same period was -8.5827 million yuan, showing a year-on-year change of 5.22% [1] - The sales gross margin was reported at 30.84% [1] Industry Comparison - Chuangguang Medical's PE (TTM) is -29.61, while the industry average is 50.64, indicating a significant disparity [2] - The company's market capitalization stands at 1.789 billion yuan, compared to the industry median of 50.67 billion yuan [2]

Core Viewpoint - Ningbo Jianxin Superconducting Technology Co., Ltd. (referred to as "Jianxin Superconducting") is the world's largest independent supplier of superconducting magnets, and its IPO process on the Sci-Tech Innovation Board has attracted significant attention as it has entered the inquiry stage [1] Financial Performance - Jianxin Superconducting's gross profit margin has significantly lagged behind its peers, with gross profit margins of 19.56%, 22.84%, and 24.94% from 2022 to 2024, while its comparable companies averaged gross profit margins of 46.27%, 45.59%, and 45.17% during the same period [4][5][6] - The company reported revenues of 359 million yuan, 451 million yuan, and 425 million yuan for the years 2022 to 2024, with net profits of 34.63 million yuan, 48.73 million yuan, and 55.78 million yuan respectively [4] Product Sales and Market Position - The company primarily engages in the research, production, and sales of core components for MRI equipment, with superconducting magnets accounting for approximately 50% of the cost of MRI equipment [4] - In terms of market share, Jianxin Superconducting ranks fifth globally and second among domestic companies in the superconducting magnet market for MRI equipment, with a projected sales revenue from superconducting products of approximately 182 million yuan, 263 million yuan, and 263 million yuan from 2022 to 2024 [4][5] Relationship with GE Healthcare - GE Healthcare, one of the three major global medical device companies, has a close relationship with Jianxin Superconducting, being both a major customer and a shareholder [8] - In 2023, GE Healthcare's subsidiary invested in Jianxin Superconducting, increasing its registered capital and becoming the ninth largest shareholder [8][9] - GE Healthcare is projected to be the third largest customer of Jianxin Superconducting in 2024, contributing sales of 37.77 million yuan, which accounts for 8.88% of the company's revenue [9] IPO and Future Prospects - Jianxin Superconducting plans to raise up to 865 million yuan through its IPO, with funds allocated for projects related to its main business, including the production of superconducting magnets [10] - The company currently has a production capacity utilization rate of 89.33% for superconducting products and 94.67% for permanent magnet products, indicating that its capacity is not yet fully saturated [10][11] - The company anticipates significant market expansion opportunities and aims to achieve more profitability through increased sales and revenue while maintaining reasonable gross margins [7]

Core Viewpoint - The article highlights the financial performance and market position of Chenguang Medical, emphasizing its focus on R&D in the medical imaging sector and its recent financial results [1]. Company Overview - Chenguang Medical specializes in the research, production, and sales of superconducting MRI equipment and core hardware, as well as specialized magnets for scientific research [1]. - The company has been recognized as a high-tech enterprise, receiving various accolades such as "Technology Small Giant Enterprise" and "Specialized and Innovative Small Giant Enterprise" in Shanghai [1]. Financial Performance - As of the first quarter of 2025, Chenguang Medical reported a revenue of 25.07 million yuan, representing a year-on-year increase of 20.21% [1]. - The net profit for the same period was -8.58 million yuan, showing a year-on-year change of 5.22% [1]. - The company's gross profit margin stood at 30.84% [1]. Market Position - Chenguang Medical's latest closing price was 20.7 yuan, with a market capitalization of 1.777 billion yuan and a price-to-book ratio of 8.10 [1]. - The company holds 91 valid patents, including 21 invention patents and 60 utility model patents, indicating a strong emphasis on innovation [1]. Industry Comparison - Chenguang Medical's price-to-earnings (P/E) ratio (TTM) is -29.41, which is significantly lower than the industry average of 50.80 [2]. - The industry median P/E ratio is 36.71, suggesting that Chenguang Medical is currently undervalued compared to its peers [2].

Group 1: Market Overview - The market has seen an increase, surpassing 4200, driven by a court ruling invalidating tariffs imposed by the US, which has boosted global risk appetite [1] - The strongest sectors today include autonomous driving and stablecoins, indicating a shift in investor focus [1] Group 2: Nuclear Fusion Research - The Southwestern Institute of Physics has achieved a new operational record for fusion devices in China, highlighting advancements in nuclear fusion research [2][1] - This development raises questions about the potential for this niche sector to gain traction and attract investment [2] Group 3: Company Involvement in Nuclear Fusion - Yongding Co., Ltd. has achieved leading performance in wire rod length and low-temperature strong magnetic field applications, with products used in superconducting induction heating and fusion magnets, maintaining close cooperation with the Southwestern Institute of Physics [6] - Chenguang Medical has ongoing technical communication with the Southwestern Institute regarding the supply of superconducting magnets, contingent on specific procurement needs [7] - Qiaoyuan Co. has established a reputation in the medical sector and maintains relationships with military research institutions, including the Southwestern Institute [8] - Lansi Heavy Industry is involved in the development of nuclear fusion-related products and has successfully applied a new type of heat exchanger in a fusion engineering project [9][10] - Guoguang Electric has received a provincial science and technology award for a project in collaboration with the Southwestern Institute focused on high-sensitivity leak detection technology for fusion components [10] - Antai Technology is at the forefront of research and manufacturing in fusion filter components, collaborating with the Southwestern Institute [11] - Hekang New Energy provides operational and maintenance services for high-voltage water-cooled variable frequency systems used by the Southwestern Institute [11] - Jingye Intelligent is exploring cooperation in remote operation and maintenance technology for fusion reactors with the Southwestern Institute [12] - Yingjie Electric serves various research institutions, including the Southwestern Institute, providing power supplies for scientific research and experimental testing [13]